Novartis says it buried studies

Share this article:

Novartis says it failed to reveal 10,000 reports of side effects. The Wall Street Journal reports that the drugmaker says it has identified at least 10,000 cases which may never have been reported and which span a variety of drugs, including Gleevec, Tasigna, Exelon and Xolair.

Novartis tells the WSJ it has passed along this information to the Japanese Ministry of Health Labor and Welfare and the FDA, among others.

Novartis has been working against a series of bad PR moments, and this latest one compounds a problem highlighted two months ago, when Novartis said it had shredded or deleted some safety reports surrounding leukemia medications Gleevec and Tasigna.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.